ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy
DAIC
APRIL 9, 2024
The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. Anthracyclines are a well-established class of cancer drugs that are used to treat several types of cancer.
105 
Let's personalize your content